Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. develops pemvidutide, a late clinical-stage dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases. Company news centers on pemvidutide development in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), including clinical trial updates and FDA designations such as Fast Track and Breakthrough Therapy Designation where granted.
Altimmune updates also cover financial results, business updates, investor conference participation and capital actions used to fund development activity. Recurring financing news includes public offerings, registered direct offerings, common stock, pre-funded warrants and common stock warrants.
Altimmune (Nasdaq: ALT) said management will attend four investor conferences March 9–12, 2026, offering one-on-one meetings and several fireside chats.
Webcasts of fireside chats at Leerink, Citizens and Barclays will be available via the company Events page; registered investors may request meetings through bank sales contacts.
Altimmune (Nasdaq: ALT) will report fourth quarter and full year 2025 financial results on March 5, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to discuss results and provide a business update.
According to Altimmune, the live webcast will be available on the company's Investor Relations website, dial-in registration is required for participants, and a replay will be accessible for up to three months.
Altimmune (Nasdaq: ALT) closed a registered direct offering raising approximately $75 million gross through sale of 17,045,454 shares of common stock (or pre-funded warrants) on Jan 29, 2026. Proceeds will fund the planned Phase 3 pemvidutide trial for MASH, plus working capital and general corporate purposes. The pre-funded warrants are exercisable immediately at $0.001 per share. Titan Partners acted as sole placement agent; the offering was made from an effective shelf registration declared effective Dec 5, 2025.
Altimmune (Nasdaq: ALT) priced a registered direct offering expected to raise approximately $75 million of gross proceeds through the sale of 17,045,454 common shares (or pre-funded warrants), with closing expected on or about January 29, 2026.
Altimmune said it intends to use net proceeds to fund preparation for its planned Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), plus working capital and general corporate purposes. The company cited Phase 2b 48-week topline data and a Breakthrough Therapy Designation from the U.S. FDA for pemvidutide.
Altimmune (NASDAQ: ALT) announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for pemvidutide to treat metabolic dysfunction-associated steatohepatitis (MASH) on January 5, 2026. The designation was based on 24-week IMPACT Phase 2b data showing statistically significant MASH resolution without worsening fibrosis and early improvements in liver fat and non-invasive fibrosis/inflammation tests.
Altimmune reported 48-week topline data in December 2025 showing further statistically significant improvements in ELF and LSM, continued weight loss at the 1.8 mg dose, and a favorable tolerability profile. The company and FDA aligned on registrational Phase 3 parameters and plan a 52-week, biopsy-endpoint Phase 3 using multiple doses and AIM-MASH AI Assist; European scientific advice will also be sought.
Altimmune (Nasdaq: ALT) reported positive 48-week topline results from the IMPACT Phase 2b trial of pemvidutide in MASH patients on Dec 19, 2025. Both 1.2 mg and 1.8 mg doses produced statistically significant improvements in noninvasive fibrosis markers versus placebo, including ELF (‑0.49 and ‑0.58 vs +0.16; p<0.0001) and LSM (‑3.04 and ‑3.97 vs ‑0.03; p<0.05/0.001).
Additional 48-week highlights: liver fat down 45.2% and 54.7% (vs 8.2% placebo), ALT reductions ~‑38 IU/L (vs ‑10.3), weight loss 4.5% and 7.5% (vs 0.2%), low discontinuations, and FDA End‑of‑Phase 2 alignment to advance to a registrational Phase 3 planned for 2026.
Altimmune (Nasdaq: ALT) announced a CEO succession: Jerry Durso will become President and Chief Executive Officer effective January 1, 2026, while retaining his role as Chairman. Vipin Garg, Ph.D. will step down as CEO and serve as an advisor through June 30, 2026.
The company highlighted progress of its lead candidate, pemvidutide (dual glucagon/GLP-1 agonist), described as Phase 3 ready for MASH. Altimmune expects to hold an End-of-Phase 2 meeting with the FDA later this quarter and to report 48-week IMPACT Phase 2b data before year-end, including NIT, weight loss, and safety data.
Altimmune (NASDAQ: ALT) announced that its management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference.
The session is scheduled for Wednesday, December 3, 2025 at 2:30 p.m. ET and will be available via webcast. Investors can access the webcast through the Events section of Altimmune's website.
Altimmune (NASDAQ: ALT) announced publication in The Lancet of 24-week IMPACT Phase 2b results for pemvidutide in MASH and a late-breaking oral presentation at AASLD The Liver Meeting® 2025 on Nov 11, 2025.
Key 24-week findings: MASH resolution occurred in 58% (1.2 mg) and 52% (1.8 mg) versus 20% for placebo; liver fat normalization reached 31% and 44% versus 4% for placebo; mean weight reductions were −4.8% and −5.8% versus −0.5% for placebo. Multiple non-invasive tests (MRI-PDFF, FibroScan, cT1, ELF, PRO-C3, FAST) showed consistent improvements and liver stiffness fell by −3.7 kPa and −2.2 kPa for active doses. Safety/tolerability were described as favorable with low discontinuation rates. Altimmune said longer-term NIT and weight-loss readouts will be provided in Q4 2025.
Altimmune (Nasdaq: ALT) reported AI-based digital pathology analysis from the IMPACT Phase 2b pemvidutide trial in MASH showing significant fibrosis reductions vs placebo at 24 weeks.
Key results: 31% of patients on pemvidutide 1.8 mg achieved ≥60% total fibrosis area reduction (n=85) vs 8% placebo (n=86; p=0.0003); early fibrosis ≥60% reduction: 34% (1.8 mg) vs 9% placebo (p<0.0001); advanced fibrosis ≥60% reduction: 27% (1.8 mg) vs 11% placebo (p=0.0063). Non-invasive tests including PRO-C3:CTX-III ratio and PRO-C6 also improved.